Esketamine Clinic Protocols: What Troche Patients Should Know

What's Being Reported

A detailed clinical overview published in Psychiatric Times on April 29, 2026 lays out how prescribers and clinics are expected to administer esketamine (brand name Spravato) in real-world practice for patients with treatment-resistant depression (TRD). The piece covers the full setup required under the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, including mandatory two-hour post-dose monitoring windows, vital sign tracking protocols, patient risk screening before each session, and recommendations for building a care team capable of handling referrals and monitoring adverse events. The article is essentially a field guide for clinicians navigating the considerable infrastructure required to offer esketamine legally and safely in an outpatient setting.

Esketamine is the S-enantiomer of racemic ketamine — the same compound family underlying compounded ketamine troches — but it is delivered as a nasal spray and administered exclusively in certified healthcare facilities under direct supervision. Unlike oral ketamine preparations, patients cannot self-administer esketamine at home under any currently approved protocol.

Why This Matters for the Ketamine Landscape

The clinical protocols described in this article underscore a structural divide that exists within ketamine-based treatment today: on one side, you have the tightly supervised, facility-bound esketamine pathway; on the other, the more flexible compounded ketamine troche model, which allows patients to follow an at-home dosing schedule under a prescriber's guidance.

The REMS requirements for esketamine are not bureaucratic noise — they exist because nasal esketamine produces rapid, potent dissociative effects with meaningful cardiovascular impact, including transient blood pressure spikes. The two-hour observation window after each dose is non-negotiable under REMS rules, which means every esketamine session demands a patient's physical presence at a clinic, plus staff time, monitoring equipment, and certified facility status. For clinics, this translates to significant overhead. For patients, it means scheduling friction, transportation logistics, and time away from work or family — every single session, which during the induction phase means twice weekly for four weeks.

Compounded ketamine troches operate under an entirely different framework. Because they are swallowed or dissolved sublingually rather than inhaled, their absorption curve is slower and their peak plasma concentration is lower and more gradual than intranasal esketamine. This pharmacokinetic profile is precisely what makes at-home administration a clinically defensible option when patients are properly screened, educated, and supervised remotely by a licensed prescriber. There is no federal REMS program governing compounded oral ketamine — it falls under state pharmacy board oversight and the prescribing physician's clinical judgment.

The Access and Workflow Gap

For patients who live in rural or underserved areas, work non-standard hours, or simply cannot commit to twice-weekly clinic visits, the esketamine pathway described in this Psychiatric Times article is, practically speaking, out of reach — even when it might be medically appropriate. This is one reason compounded ketamine troches have grown as a treatment option: they extend access to a class of medication that would otherwise require substantial clinical infrastructure.

That said, the protocols detailed for esketamine are worth understanding even if you are currently on a troche regimen. The monitoring emphasis — vital signs before and after dosing, screening for dissociation severity, identifying patients with cardiovascular contraindications — reflects broadly applicable safety thinking for any ketamine-based treatment. Responsible troche prescribers apply analogous screening logic at intake and during follow-up check-ins, even without a formal REMS obligation.

One practical implication: if your current troche provider is not asking about blood pressure history, cardiovascular conditions, or baseline dissociative symptoms before initiating or adjusting your dose, that is a gap worth flagging. The esketamine clinical framework makes explicit what good ketamine prescribing looks like regardless of delivery format.

Troches vs. Esketamine: A Side-by-Side Reality Check

The Psychiatric Times piece focuses entirely on esketamine, but reading it through the lens of compounded troche therapy surfaces some useful contrasts worth keeping in mind as a patient:

• Supervision model: Esketamine requires in-person clinical supervision every session. Troches are typically self-administered at home, with remote prescriber oversight and scheduled check-ins.
• Frequency flexibility: Esketamine induction is protocol-fixed (twice weekly). Troche dosing schedules are individualized and can be adjusted based on response without a clinic visit.
• Cost and coverage: Esketamine (Spravato) is FDA-approved and increasingly covered by insurance, but the clinic visit overhead adds cost. Compounded troches are not FDA-approved and are rarely covered by insurance, but total cost per session is often lower.
• Monitoring burden: Esketamine monitoring is outsourced to the clinic. With troches, that responsibility is shared between you and your prescriber — which requires patient engagement and honest self-reporting.
• Bioavailability: Intranasal esketamine has higher and faster bioavailability than oral ketamine. Troches, particularly sublingual preparations held under the tongue, improve absorption over swallowed tablets but still deliver a more gradual effect profile.

The Bottom Line

The detailed esketamine clinical guidance published this week is a reminder that ketamine-based treatment — in all its forms — carries real pharmacological weight and requires structured oversight. The troche pathway's relative flexibility is a genuine advantage for access and adherence, but it works best when patients and prescribers treat that flexibility as a responsibility, not a shortcut. As the ketamine treatment field matures, expect more clinical literature like this to set de facto standards that influence how all ketamine modalities, including compounded oral options, are evaluated by payers, regulators, and patients alike.

Read the original clinical overview at Psychiatric Times.